MBRX - Moleculin's WP1066 shows encouraging action in early-stage pediatric brain tumor study

Moleculin Biotech ([[MBRX]] +3.4%) announced interim first cohort data from the Emory University physician-sponsored Phase 1 trial, with WP1066 (AflacST1901) for the treatment of childhood brain tumors.First three patients received WP1066 dose level of 4 mg/kg with no adverse events related to the candidate was observed and the study will now proceed to the next higher dose of 6 mg/kg.One of these patients with diffuse intrinsic pontine glioma, showed an apparent response with both clinical improvement and radiologic reduction of tumor size.WP1066 is an immuno-stimulating p-STAT3 inhibitor.

For further details see:

Moleculin's WP1066 shows encouraging action in early-stage pediatric brain tumor study